Navigation Links
VirtualScopics to Present at Two Upcoming Investor Conferences
Date:11/3/2008

ROCHESTER, N.Y., Nov. 3 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading provider of quantitative imaging for clinical trials, announced today that Ms. Molly Henderson, the company's chief business and financial officer, will be presenting a corporate and financial overview at two upcoming investor conferences. Ms. Henderson will be presenting on November 6, 2008 at the Western New York Investors Conference in Buffalo, New York. Additionally, Ms. Henderson will be presenting at the Rodman & Renshaw Annual Global Investment Conference at The New York Palace Hotel in New York City.

Ms. Henderson's presentation at the Rodman & Renshaw Annual Global Investment Conference is scheduled for November 12, 2008 at 2:25 pm EST. A live webcast of the presentation will be available in the Investor Relations section of the company's website, http://www.virtualscopics.com .

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit http://www.virtualscopics.com .

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards in 2008 and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at http://www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

CONTACT: Company Contact:

Molly Henderson

Chief Business and Financial Officer

500 Linden Oaks

Rochester, New York 14625

(585)249.6231


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. VirtualScopics Schedules Third Quarter 2008 Earnings Announcement
2. VirtualScopics Reports Second Quarter 2008 Results
3. VirtualScopics Receives NASDAQ Delisting Notice; Company Files Appeal to Stay Delisting
4. VirtualScopics Backlog Exceeds a Record $20 Million
5. VirtualScopics Announces $4.35 Million Private Placement
6. Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
7. BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
8. LCA-Vision to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
9. NMB's Fans and Blowers to be Represented in Canada by CST-Arwin
10. The Ensign Group to Present at the Oppenheimer 19th Annual Healthcare Conference
11. Satellite Healthcare Will Present at the American Society of Nephrology's Renal Week – Booth 527 : November 4-9, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... in Carnegie, OK, from Dr. Jamie Cameron, with or without a referral. ... to traditional orthodontic treatment. Depending on each patient’s case, treatment with the FASTBRACES ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... buildings (MOBs) and other outpatient facilities, and who are the most active developers? ... those questions, Revista and Healthcare Real Estate Insights (HREI) found that outpatient medical ...
(Date:3/29/2017)... ... March 29, 2017 , ... An inventor from ... rubber bands used in conjunction with my braces always rubbed against the inside ... way to prevent this problem." The O.B.S. was the result of his brainstorming. ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one ... cancers and is touted to be the next revolution in our fight against this ... in the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who manage some ... Time Square, New York. , The program will be led by co- ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Wound care devices and products are used ... The industry mainly consists of establishments engaged in manufacturing ... wounds caused by mechanical, chemical, thermal, and radiogenic trauma; ... diabetes, skin related diseases, immunological diseases, and other chronic ... the largest region in the wound care devices market ...
(Date:3/29/2017)... Avelas Biosciences, Inc., a clinical stage oncology-focused company dedicated to improving ... Carmine N. Stengone , president and chief executive officer, will present ... th Annual Healthcare Conference on Wednesday, April 5, 2017, at ... Hotel in New York City . ... ...
(Date:3/29/2017)... , March 29, 2017 Today, CVS Health officials ... Kim Reynolds , Department of Public Health Director Gerd ... Steve Lukan in announcing the availability of the opioid ... locations in Iowa.  CVS Health has established a standing order ... CVS Pharmacy to expand access to the medication in the ...
Breaking Medicine Technology: